Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

被引：27
作者：
Huiberts, Anne J. [1 ]
de Gier, Brechje [1 ]
Hoeve, Christina E. [1 ]
de Melker, Hester E. [1 ]
Hahne, Susan J. M. [1 ]
den Hartog, Gerco [1 ,2 ]
van de Wijgert, Janneke H. H. M. [1 ,3 ]
van den Hof, Susan [1 ]
Knol, Mirjam J. [1 ]
机构：
[1] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands
[2] Radboudumc, Radboud Ctr Infect Dis, Nijmegen, Netherlands
[3] Univ Med Ctr Utrecht UMCU, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
来源：
EUROSURVEILLANCE | 2023年 / 28卷 / 07期
关键词：
D O I：
10.2807/1560-7917.ES.2023.28.7.2300087
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18- 59-year-olds and 14% in 60- 85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID- 19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.
引用
收藏
页数：7
相关论文
共 13 条
  • [1] Andersson NW, 2023, MEDRXIV, V2023, DOI [10.1101/2023.01.19.23284764, DOI 10.1101/2023.01.19.23284764]
  • [2] Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression
    Bobrovitz, Niklas
    Ware, Harriet
    Ma, Xiaomeng
    Li, Zihan
    Hosseini, Reza
    Cao, Christian
    Selemon, Anabel
    Whelan, Mairead
    Premji, Zahra
    Issa, Hanane
    Cheng, Brianna
    Abu Raddad, Laith J.
    Buckeridge, David L.
    Van Kerkhove, Maria D.
    Piechotta, Vanessa
    Higdon, Melissa M.
    Wilder-Smith, Annelies
    Bergeri, Isabel
    Feikin, Daniel R.
    Arora, Rahul K.
    Patel, Minal K.
    Subissi, Lorenzo
    [J]. LANCET INFECTIOUS DISEASES, 2023, 23 (05) : 556 - 567
  • [3] de Gier B, 2023, MEDRXIV, V2023, DOI [10.1101/2023, DOI 10.1101/2023]
  • [4] EMA, 2022, 1 AD COVID 19 BOOST
  • [5] Huiberts A, DESIGN BASELINE DESC, DOI [10.21203/rs.3.rs-1645696/v1, DOI 10.21203/RS.3.RS-1645696/V1]
  • [6] Huiberts AJ, 2023, MEDRXIV, V2023, DOI [10.1101/2023, DOI 10.1101/2023]
  • [7] Link-Gelles R, 2022, MMWR-MORBID MORTAL W, V71, DOI 10.15585/mmwr.mm7148e1
  • [8] Rijksinstituut voor Volksgezondheid en Milieu (RIVM), 2023, VAR HET COR SARSCOV2
  • [9] Rijksinstituut voor Volksgezondheid en Milieu (RIVM). RIVM COVID-19 epidemiologie en surveillance team, COVID 19 HOSP INT CA
  • [10] Rijksoverheid, COR DASHB POS TESTS
12